Plasma and Cerebrospinal Fluid Pharmacokinetics of Moxifloxacin in a Patient with Tuberculous Meningitis

This publication has 14 references indexed in Scilit:

• Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
  Clinical Infectious Diseases, 2007
• Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs
  Respiratory Medicine, 2006
• Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 2006
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America
  American Journal of Respiratory and Critical Care Medicine, 2003
• Long-Term Tolerance and Effectiveness of Moxifloxacin Therapy for Tuberculosis: Preliminary Results
  Journal of Chemotherapy, 2003
• In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis
  International Journal of Antimicrobial Agents, 2002
• Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis
  Antimicrobial Agents and Chemotherapy, 2002
• Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis
  Antimicrobial Agents and Chemotherapy, 2001
• Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration
  Clinical Pharmacokinetics, 2001
• Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in Rabbits
  Antimicrobial Agents and Chemotherapy, 1998